Guardant Health 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third quarter revenue increased 36% year over year to $361 million from $265 million.
- Oncology revenue increased 25% to $231 million, while oncology test volume rose 58% to 117,000 tests from 74,000.
- Guardant360 Liquid volume grew nearly 30%; Reveal volume grew well in excess of 100% according to management, and Guardant360 Tissue recorded record sequential growth.
- Biopharma and data revenue increased 8% to $59 million, and the business recorded its highest-ever quarterly test volume.
- Screening revenue increased 180% to $68 million from $24 million, while Shield volume grew 246% to 83,000 tests from 24,000.
- Shield average selling price was above $800, and Shield cost per test declined from $410 in Q2 to $330 in Q3, surpassing the year-end target of $350 a full quarter ahead of schedule.
- Third quarter non-GAAP gross margin was 67%, compared with 66% a year ago; non-GAAP operating expenses were $287 million, up 26%.
- Adjusted EBITDA loss was $37 million, compared with a loss of $46 million in the third quarter of 2025; quarter-end cash and investments were $1.1 billion.
- Free cash flow burn was $37 million in the third quarter, compared with $46 million in the prior-year period.
- Guardant received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH and submitted a PMA application for Guardant360 Tissue to the FDA.
- Guardant reported 31 cumulative companion diagnostic approvals globally and more than 1.5 million patient tests and more than 900,000 epigenetic profiles across more than 100 tumor types.
- Guardant Reveal detected 81% of distant recurrences in the COSMOS-MEL01 melanoma study with 100% specificity, with circulating tumor DNA detected an average of approximately three months before clinical identification of recurrence.
- Reveal Ultra had processed more than 4,000 samples across multiple studies, and Guardant said it plans to bring the test to clinical customers before year-end.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
We'll now hand the conference over to Zarak Khurshid, VP of Investor Relations. Zarak, please go ahead. Thank you.
Earlier today, Guardant Health released financial results for the third quarter ended September 30, 2026. Joining me today from Guardant are Helmy Eltoukhy, Co-CEO, AmirAli Talasaz, Co-CEO, and Mike Bell, Chief Financial Officer. Before we begin, I'd like to remind you that during this call, we will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items. Additional information regarding material risks and uncertainties, as well as the non-GAAP financial reconciliation to most directly comparable GAAP financial measures, are available in the press release Guardant issued today, as well as in our 10-Q and other filings with the SEC.
Guardant disclaims any intention or obligation to update or revise financial projections and forward-looking statements, whether because of new information, future events, or otherwise, except as required by law. The information in this conference call is accurate only as of the live broadcast. With that, I would like to turn the call over to Helmy.
Thank you, Zarak, and thank you for joining our third quarter 2026 earnings call. At Guardant, our mission is to conquer cancer with data, and the third quarter showed that strategy working across the company. Our Smart Platform underpins four of the largest opportunities in precision medicine: therapy selection, MRD, cancer screening, and over time, multi-disease screening. At its core is a proprietary multimodal view of cancer biology, integrating genomic, epigenomic, and other molecular signals with clinical and outcomes data across millions of patient samples. Powered by our growing datasets and AI, the platform continuously learns from every test we run, deepening our understanding of disease biology and translating those insights into increasingly powerful products across the disease continuum. Every commercial product runs on the platform, and it continues to deliver increasing clinical insights across the disease continuum.
Before I share our results in more detail, I want to share a story that captures why we come to work every day. A 56-year-old woman was diagnosed with stage 3 colorectal cancer. Her oncologist ordered Guardant360 Liquid, followed by Reveal therapy monitoring tests to both profile and track her cancer. Guardant360 Liquid showed no actionable alterations, so she began treatment with chemotherapy, and her oncologist used monthly Reveal tests to track her progress. Her first two Reveal results were positive for cancer. By the third blood draw, she was struggling with treatment and questioning whether to continue. That third result came back with no cancer signal detected. It gave her and her oncologist concrete evidence that chemotherapy was working and the confidence to keep going. She has since completed treatment. Two more Reveal results and recent diagnostic imaging show no evidence of disease.
Her oncologist has now shifted to using Reveal for long-term surveillance to monitor for recurrence. This patient's journey beautifully illustrates the power of the ecosystem we have built, one platform helping oncologists guide care at every step, from therapy selection to treatment monitoring to MRD and long-term surveillance. Turning to our revenue performance on slide four. Third quarter revenue grew 36% to $361 million, up from $265 million a year ago. The business continues to fire on all cylinders, with stellar execution across every major function in the company. Moving to slide five. Oncology delivered another excellent quarter, with the revenue growing 25% year-over-year to $231 million. Oncology test volumes rose 58% to 117,000 tests, up from 74,000 in the prior year period.
This growth is driven by strength across our portfolio of therapy selection and monitoring products, powered by increasing clinical utility from our Smart Apps and the increasing interconnectivity of our solutions across late-stage and early-stage disease. Turning to slide six. Continuous product innovation fueled our oncology volume growth. Each product launch and waves of Smart App upgrades, supported by reimbursement and regulatory catalysts, has added momentum, which drove year-over-year oncology volume growth of 58%. Guardant360 Liquid volume grew nearly 30% in the third quarter and is on track for roughly 30% volume growth for the full year. Guardant360 Tissue remained our second-fastest growing oncology product, with record sequential growth, and Reveal continues to be the fastest, with volume growth well in excess of 100%. On slide seven. In September, we received landmark FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH.
The test identifies emerging ESR1 mutations in patients with advanced breast cancer before disease progression is visible on imaging, providing oncologists with information that can help inform an earlier treatment change. In the U.S., roughly 37,000 women are living with HR-positive, HER2-negative advanced breast cancer. With testing recommended every three months, Guardant360 CDx can help these women and their oncologists track how the disease is changing and identify the right treatment at each step of their care. Not only is this the first monitoring approval for Guardant360 CDx, it's the first of its kind FDA-approved therapy and companion diagnostic protocol built to inform a therapy switch upon molecular emergence of a drug resistance marker. We believe this approval and groundbreaking paradigm could provide a blueprint for future switch studies and therapies in other indications.
A future where therapy switching, escalation, and de-escalation are guided more precisely and earlier by signals in the blood, rather than waiting for course changes on imaging. Moving to slide eight. With this approval, Guardant360 CDx is the only FDA-approved companion diagnostic for ESR1-targeted therapies. For oncologists, that means one validated test to initially measure and serially track the evolution of a patient's ESR1 status, regardless of which ESR1-targeted therapy is ultimately chosen. While it remains early in the launch of ETCAMAH, we continue to hear very encouraging feedback from the oncology community and from the AstraZeneca team. On slide nine, you will see that we have executed on the key steps towards establishing an improved Guardant360 Liquid CDx reimbursement rate in 2027. The PLA code was recently finalized in October, which provides us with a dedicated billing code, and our ADLT application was recently submitted.
We remain on track for ADLT designation in the first half of 2027. Moving to slide 10. We are excited to announce that we have submitted our PMA application for Guardant360 Tissue to the FDA, a milestone that reflects our team's tireless work and a culmination of multiple major upgrades over the past two years that have made it a best-in-class test. As a reminder, Guardant360 Tissue is the only multi-omics assay combining comprehensive DNA profiling, whole transcriptome RNA, and genome-wide methylation analysis in a single test. It also has one of the lowest sample input requirements of any CGP tissue test, helping us deliver comprehensive answers when tissue is limited. Moving to slide 11. Data is the fuel behind every one of our products. We have now run more than 1.5 million patient tests and generated more than 900,000 epigenetic profiles across more than 100 tumor types.
This data powers our InfinityAI learning engine. We combine genomic, epigenomic, claims, longitudinal, and EMR data, and InfinityAI transforms it into novel insights, new products, and real-world evidence that can help our biopharma partners move faster to regulatory approvals. We have also recently piloted new decision support tools built on InfinityAI. These tools bring together a patient's clinical history with guideline-informed treatment options supported by real-world data. A conversational AI agent then provides physicians with concise, patient-specific summaries and allows them to explore questions directly within the workflow. Turning to slide 12. We continue to deliver on the promise of InfinityAI. Next week, we are launching the fourth wave of Smart Apps on Guardant360 Liquid, which represents another major upgrade to the product and the second-largest Smart App launch in our history. This wave includes 11 Smart App releases.
For the first time, it introduces Smart Apps that use methylation signatures to predict therapy benefit. One example is our SERD benefit predictor, which gives physicians new insight into whether a patient's breast cancer is estrogen-dependent. That information may indicate how the patient may respond to SERD therapy. We are also launching two new apps for advanced lung cancer designed to help physicians select immunotherapy. The first helps identify patients more likely to benefit from immunotherapy alone, while the second provides information on the key biomarker PD-L1 directly from a blood draw, which has traditionally required tissue, addressing an important challenge in lung cancer where tissue is often difficult to obtain. Alongside these new apps, we are expanding the existing capabilities of Guardant360 Liquid with new methylation-enhanced features.
These upgrades help the test detect more types of genomic changes, pinpoint where a cancer originated when that is unclear, and more precisely classify breast and lung cancers. The result is a more complete picture for physicians from a single blood test, which strengthens our competitive position. We believe we are still in the early innings of the Smart App story, with dozens more features currently in development. Moving on to slide 13. Reveal's evidence pipeline continues to progress in support of indication expansion. We recently published results showing Guardant Reveal utility in melanoma across a diverse set of subtypes. Slide 14 highlights the results from COSMOS-MEL01, a melanoma study recently published in Cancer Research Communications. It's the first published prospective multicenter study of Guardant Reveal in patients with resected stage II to III melanoma. Reveal detected 81% of distant recurrences while demonstrating 100% specificity.
Importantly, circulating tumor DNA was detected with an average lead time of approximately three months before the recurrence was identified clinically. We look forward to MolDX submission for Reveal melanoma in the coming months. Turning to slide 15. We have made tremendous progress with Reveal Ultra, the newest addition to our oncology portfolio. The assay demonstrates what we believe to be market-leading sensitivity, with a limit of detection at one part per million or below across major tumor types, extending our ability to find residual disease at extraordinarily low levels. We're also advancing a substantial clinical validation program with more than 4,000 samples processed to date across multiple studies. We recently launched Reveal Ultra to our biopharma partners and are extremely pleased with the performance we are seeing, giving us increasing confidence as we prepare to bring Reveal Ultra to clinical customers before year-end.
We believe Reveal Ultra has the potential to set a much higher bar for performance in MRD and unlock a significant new growth opportunity for our oncology business. Turning to our biopharma and data business on slide 16. Revenue reached $59 million in the third quarter, up 8% from $55 million a year ago. Q3 was a strong quarter from a regulatory perspective as well, with three new companion diagnostic approvals, bringing our cumulative total to 31 globally. Each of these approvals strengthens our deep ties to biopharma and helps further establish us as a key partner for design of future therapies. With that, I'll now turn the call over to AmirAli for an update on screening.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
18 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
